Navigation Links
NeuroQuest Close to Validation Trial for Biomarker Platform in Diagnosis of Alzheimer's
Date:12/10/2012

TEL AVIV, Israel, December 10, 2012 /PRNewswire/ --

NeuroQuest, a company of the Trendlines Group's Misgav Venture Accelerator is moving quickly towards an important validation trial for novel blood-based immune biomarkers for the diagnosis of Alzheimer's disease. The company's biomarker platform for neurodegenerative diseases is based on the research of Prof. Michal Schwartz, Chair of Neuroimmunology at the Weizmann Institute of Science who pioneered the concept of Protective AutoImmunity. The trial is a follow-up to the preliminary human trial performed at Sheba, Rambam, and Abarbanel Medical Centers in Israel and Methodist Neurological Institute in Houston, Texas which demonstrated up to 85% diagnostic accuracy and specificity in AD and ALS patients in mild to moderate stages versus healthy controls. The success of the validation trial would present a new approach for a simple, inexpensive, and early diagnosis of Alzheimer's disease. Successful results may lead to new therapeutic targets for this disease, opening new directions to an industry searching for novel approaches to combat AD, given the recent failures of several Phase III trials for therapeutics targeting Beta-Amyloid reduction.

Dr. Jacobo Mintzer, Co-Director of Alzheimer's Research & Clinical Programs of the Medical University of South Carolina, has joined the company as its new VP of Clinical affairs to leverage his experience in over 200 Alzheimer's-related clinical trials. NeuroQuest has also announced a new partnership with the Harvard Clinical Research Institute and their Senior Director of Clinical Program Management, Dr. Jennifer Buell. Together the teams are gearing up for a 150-200 patients clinical trial at MUSC, Harvard, and other medical centers to validate the company's novel immune-based biomarkers for Alzheimer's Disease.

The company has confirmed financing totaling $500,000 led by InterTech Group, headed by Jonathan Zucker, and the Maryland/Israel Trendlines Fund. The company is also in serious discussions with the South Carolina Research Authority (SCRA) about a grant to support opening a US development center in Charleston, SC as the base of its clinical and regulatory work. Many of these developments were put into motion following a 2011 American Israel Chamber of Commerce - South East's (AICC-SE) delegation from South Carolina headed by Tom Glaser. Glaser's group, returned to Israel and Misgav again this week to celebrate and investigate additional opportunities for collaboration and investment.

Contact:
Efrat Kaduri
Ofir Shpigel Media and Public Relations
+972-4-9535030
Efrat@ofirpr.co.il


'/>"/>
SOURCE NeuroQuest
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Wright Therapy Products, Inc. Closes $3 million Financing Round
2. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
3. Edison Pharmaceuticals Closes $20M Series F Financing
4. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
5. DenTech China 2012 Closed with Success
6. Agnitio Sets Up Asia HQ in Shanghai and is the First to Bring the Combined Closed Loops of Marketing and E-Learning to the Pharmaceutical Industry
7. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
8. Novelos Therapeutics Closes $2 Million Private Placement
9. ClosedWon Launches QuickQuote at Dreamforce 2012 on Salesforce.coms AppExchange, the Worlds Most Popular Cloud Marketplace for Social Apps for Business
10. RxAnte Closes Series A Financing
11. Aethlon Medical Discloses MD Anderson Cancer Center Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... , June 23, 2016 ... but it continues to present great opportunities to investors. ... for today: Intrexon Corp. (NYSE: XON ), ... Pharmaceuticals Inc. (NASDAQ: ARNA ), and Regeneron ... about these stocks and receive your complimentary trade alerts ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):